AI Just Minted $10 Trillion and You Own None of It. These 4 ETFs Put You in the Game

The article argues that AI-linked capital spending is supporting U.S. growth and highlights four ETFs for diversified exposure: QQQ, SMH, BOTZ, and IGV. SMH has been the standout, up 75.49% year to date and 127.69% over the past year, while QQQ is up 17.87% YTD, BOTZ 1.74%, and IGV is down 14.89% YTD. The piece is broadly constructive on AI exposure but cautions that valuations are elevated and the funds are highly correlated, especially after SMH fell 5.52% in the past week.

Analysis

The cleanest second-order read is that the AI capex cycle is no longer just an NVDA story; it is migrating down the stack into AVGO, AMD, ASML, LRCX, and AMAT, where margins and order visibility can stay elevated even if the headline AI trade gets crowded. That said, the semiconductor complex is now vulnerable to a classic late-cycle problem: the market is pricing multi-year demand before end-demand has proven out, so any pause in hyperscaler spending can hit the group faster than fundamentals deteriorate.

Within this basket, AVGO has the best mix of AI leverage and ballast because software-linked cash flows can dampen the drawdown if hardware spending wobbles, while AMD remains the most asymmetrical catch-up name if accelerators stay constrained and share shifts continue. NVDA is still the cleanest expression of the theme, but it is also the most exposed to sentiment reversal because it is increasingly owned as a macro proxy, not just a company-specific winner. ASML, LRCX, and AMAT are more interesting as delayed beneficiaries: their order books should be less volatile day-to-day, but their multiple expansion will lag until the market believes capex is durable beyond the current wave.

The bigger contrarian miss is that software could be the eventual loser even if AI wins broadly. If customers keep deploying tokens and inference internally without near-term subscription uplift, IGV-type names may remain a value trap until monetization is visible in margins, not just in product demos. ISRG is a useful tell on whether physical AI/automation is becoming real outside the data center; if industrial and healthcare automation budgets reaccelerate into 2025, BOTZ should start to outperform the pure software sleeve despite its weaker recent tape.

Risk is mostly a 1-6 month horizon issue: if capex guidance from hyperscalers inflects lower, SMH will likely gap first and drag the rest of the basket with it. Over a 12-24 month horizon, the main upside catalyst is a broader diffusion of AI spend into enterprise automation and workflow software, which would justify owning the enablers rather than chasing the leaders at peak enthusiasm.

Key Decisions for Investors

• Go long AVGO vs. short IGV for 3-6 months: best expression of 'AI monetization eventually shows up in infrastructure first'; favorable if software rev rec lags while AI capex remains firm.
• Buy AMD on pullbacks over the next 2-8 weeks and use NVDA as the funding short only if positioning data shows further crowding; AMD offers the cleaner upside torque if accelerator share gains continue, but it needs discipline on sizing.
• Reduce outright SMH exposure into strength and replace with a barbell of AVGO + ASML/LRCX over 3-6 months: same AI capex theme with lower single-factor sensitivity and better downside defense if the hardware cycle cools.
• Initiate a small long BOTZ vs. short IGV pair for 6-12 months: if AI shifts from model training to physical deployment, automation should re-rate before software revenue catches up.
• For tactical traders, buy 3-6 month call spreads in NVDA or SMH only on post-earnings drawdowns; avoid chasing strength because the risk/reward degrades sharply once implied capex optimism is fully priced.